Intravesical immunotherapy with BCG is the most effective intravesical therapy for CIS and T1 tumors of the bladder. Although intravesical BCG is used to treat high-risk Ta, T1, and CIS tumors, it is not as effective in reducing the 5-year recurrence rate for other low-grade and low-stage urothelial carcinomas.
When given as a maintenance therapy, intravesical docetaxel may increase the duration of recurrence-free survival in patients with BCG-refractory non–muscle-invasive bladder cancer (NMIBC).
Interferon alfa or interferon gamma as a monotherapy, or in combination with intravesical BCG immunotherapy, has been used to treat urothelial carcinoma at stages Ta and T1 and CIS. Both interferons have been primarily used after failure of BCG monotherapy.
Learn more about the treatment of NMIBC.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Bladder Cancer Management - Medscape - Jan 13, 2020.